TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03858504

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The children with enthesitis related arthritis will be randomized into one of the exercise groups as yoga or home exercises and will perform the exercise program for 2 times a week for 8 weeks according to their groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The children with enthesitis related arthritis will be randomized into one of the exercise groups as yoga or home exercises and will perform the exercise program for 2 times a week for 8 weeks according to their groups.
Study: NCT04588155

Intervention type: DEVICE
Intervention: Functional assessment
Description: Timed Up and Go Test administration with application of Inertial Measurement Unit for a temporal and kinematic assessment of movement performed during test esecution

Intervention type: DEVICE
Intervention: Functional assessment
Description: Timed Up and Go Test administration with application of Inertial Measurement Unit for a temporal and kinematic assessment of movement performed during test esecution

Intervention type: OTHER
Intervention: Clinical assessment
Description: Roland Morris Disability Questionnaire (RMDQ) to assess the level of functional impairment and disability in the activity of daily living~Numerical Pain Rating System (NPRS) administration to quantify level of pain experienced just before the TUG test execution
Study: NCT01029444

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsatile Intravenous Insulin Therapy (Humulin, Humulog, Novolog )
Description: Patients receive weekly treatments of Pulsatile Intravenous insulin therapy. The patient's Endocrinologist determines the insulin dosage each week based upon the patient's response to treatment RQ levels and their insulin resistance.
Study: NCT01608451

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Inj Arachitol 300,000 I.U/ml IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Inj Arachitol 300,000 I.U/ml IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inj. Progesterone
Description: Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inj. Progesterone
Description: Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
Study: NCT02210091

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
Description: Pharmacokinetic (PK) analysis of ADVATE

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
Description: Pharmacokinetic (PK) analysis of ADVATE

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEGylated Recombinant Factor VIII
Description: Pharmacokinetic (PK) analysis of BAX 855

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEGylated Recombinant Factor VIII
Description: Pharmacokinetic (PK) analysis of BAX 855

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEGylated Recombinant Factor VIII
Description: Prophylaxis treatment
Study: NCT02583490

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: spectrum 5000Q ECT device (RUL ECT)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spectrum 5000Q ECT device (RUL LAP ECT)
Study: NCT02210091

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEGylated Recombinant Factor VIII
Description: Prophylaxis treatment
Study: NCT01256762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat sodium
Description: Imetelstat is administered at a dose of 300 mg/m2 on day one of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is administered at 15 mg/kg on day one of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is administered at 15 mg/kg on day one of a 21 day cycle
Study: NCT00515242

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: relaxing environment
Description: time in a relaxing environment
Study: NCT02514824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: Investigational mTOR kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: Investigational mTOR kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: Investigational mTOR kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: Investigational mTOR kinase inhibitor
Study: NCT00886834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 400 micrograms inserted vaginally or buccally, per the participants desire prior to the IUD insertion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pills which are identical to the study drug in appearance, taste, and smell.
Study: NCT01138657

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by a 40 mg dose eow starting at Week 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all participants continuing in the study were to discontinue prednisone no later than Week 15.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Administered orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all participants continuing in the study were to discontinue prednisone no later than Week 15.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study: NCT01357902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Lamotrigine is a selective inhibitor of a voltage-sensitive sodium channel, is an anti-epileptic drug of the phenyltriazine class.
Study: NCT01048164

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Massage
Description: Chair Massage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Massage
Description: Chair Massage
Study: NCT04314258

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moringa oleifera tea
Description: 4 grams of Moringa oleifera tea twice daily
Study: NCT00382382

Intervention type: OTHER
Group type: OTHER
Intervention: diffusion tensor imaging (DTI)
Description: Both groups will have a diffusion tensor imaging (DTI) perform.

Intervention type: OTHER
Group type: OTHER
Intervention: diffusion tensor imaging (DTI)
Description: Both groups will have a diffusion tensor imaging (DTI) perform.
Study: NCT04647708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049
Description: Participants will receive low oral dose of M5049, twice daily in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049
Description: Participants will receive ascending oral dose of M5049, twice daily in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049
Description: Participants will receive ascending oral dose of M5049, twice daily in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049
Description: Participants will receive ascending oral dose of M5049, twice daily in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049
Description: Participants will receive high oral dose of M5049, twice daily in Part B.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to M5049.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to M5049.
Study: NCT04622878

Intervention type: PROCEDURE
Group type: OTHER
Intervention: thrombectomy and PTA
Description: open femoral access with fogarty catheter then PTA with balloon and possible stenting if needed
Study: NCT02198911

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NO GUM
Description: For the NO GUM condition, participants will not chew gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NO GUM
Description: For the NO GUM condition, participants will not chew gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NO GUM
Description: For the NO GUM condition, participants will not chew gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MCC (Mint Chocolate Chip gum)
Description: For the MCC gum condition, participants will chew MCC gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MCC (Mint Chocolate Chip gum)
Description: For the MCC gum condition, participants will chew MCC gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MCC (Mint Chocolate Chip gum)
Description: For the MCC gum condition, participants will chew MCC gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: C (Cinnamon gum)
Description: For the C gum condition, participants will chew Cinnamon gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: C (Cinnamon gum)
Description: For the C gum condition, participants will chew Cinnamon gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: C (Cinnamon gum)
Description: For the C gum condition, participants will chew Cinnamon gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
Study: NCT00408005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asparaginase
Description: Given IM or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT, IV, or SC
Study: NCT01256762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is administered at 90 mg/m2 on days one and eight of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is administered at 90 mg/m2 on days one and eight of a 21 day cycle
Study: NCT04082780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifamycin SV MMX
Description: Intervention arm

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm
Study: NCT03199521

Intervention type: OTHER
Intervention: Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)
Description: Global Thrombosis Test (GTT): assesses formation of the blood clot and how easily can this be broken down once formed) Thromboelastography (TEG) :assesses the properties of a blood clot and how easily can be broken down Thrombin generation assays: assesses the formation of a blood clot and the potential of thrombolysis via the introduction of different buffer solutions

Intervention type: OTHER
Intervention: Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)
Description: Global Thrombosis Test (GTT): assesses formation of the blood clot and how easily can this be broken down once formed) Thromboelastography (TEG) :assesses the properties of a blood clot and how easily can be broken down Thrombin generation assays: assesses the formation of a blood clot and the potential of thrombolysis via the introduction of different buffer solutions

Intervention type: OTHER
Intervention: Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)
Description: Global Thrombosis Test (GTT): assesses formation of the blood clot and how easily can this be broken down once formed) Thromboelastography (TEG) :assesses the properties of a blood clot and how easily can be broken down Thrombin generation assays: assesses the formation of a blood clot and the potential of thrombolysis via the introduction of different buffer solutions
Study: NCT02780973

Intervention type: OTHER
Intervention: Wearing of an intraoral device with bovine tooth samples
Description: Wearing of an intraoral device with bovine tooth samples

Intervention type: OTHER
Intervention: Wearing of an intraoral device with bovine tooth samples
Description: Wearing of an intraoral device with bovine tooth samples
Study: NCT02520739

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Virgin Olive Oil (VOO)
Description: VOO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of VOO distributed over 3 meals. Daily doses of VOO were blindly prepared in special containers, with the corresponding 30 mL VOO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed VOO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Optimized High Phenolic Content Oil (OHPCO)
Description: OHPCO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of OHPCO distributed over 3 meals. Daily doses of OHPCO were blindly prepared in special containers, with the corresponding 30 mL OHPCO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed OHPCO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Functional Olive Oil (FOO)
Description: FOO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of FOO distributed over 3 meals. Daily doses of FOO were blindly prepared in special containers, with the corresponding 30 mL FOO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed FOO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
Study: NCT04507165

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral block+Anterior serratus plane block
Description: Paravertebral block will be performed at T3 and T7 level on the surgical side using out-of-plane approach under ultrasound-guided, with 0.5% ropivacaine 10ml at each injection site. Anterior serratus plane block will be performed at the 4th rib level on the surgical side under ultrasound-guided, with 0.5% ropivacaine 15ml. The blocking range is measured by ice cube method 15 minutes after the procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paravertebral block+Anterior serratus plane block
Description: Paravertebral block will be performed at T3 and T7 level on the surgical side using out-of-plane approach under ultrasound-guided, with 0.5% ropivacaine 10ml at each injection site. Anterior serratus plane block will be performed at the 4th rib level on the surgical side under ultrasound-guided, with 0.5% ropivacaine 15ml. The blocking range is measured by ice cube method 15 minutes after the procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: opioid free anesthesia
Description: Anesthesia induction: Dexmedetomidine 1µg/kg (intravenous infusion within 10min), propofol 1.5-2mg/kg (intravenous bolus), lidocaine 1.5-2mg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus), and 0.5% tetracaine 5ml for surface anesthesia of the throat.~Maintenance of anesthesia: Continuous infusion of propofol and dexmedetomidine \[0.4μg/(kg.h)\]. The infusion rate of propofol was adjusted according to bispectral index value. Cisatracurium besylate was given as needed. Flurbiprofen 50mg was given intravenously before the skin incision and suture respectively.~Remedy: If blood pressure rises (more than 30% of the mean arterial pressure after induction), and heart rate increases (more than 30% of heart rate after induction) during skin incision, lidocaine 1.5mg/kg will be given intravenously and then be continuously infused at a rate of 1.5mg/(kg.h).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: opioid based anesthesia
Description: Anesthesia induction: Propofol 1.5-2mg/kg (intravenous bolus), sufentanil 0.3μg/kg (intravenous bolus), cisatracurium besylate 0.15-0.3mg/kg (intravenous bolus before tracheal intubation), methylprednisolone 40mg (intravenous bolus), esmolol 1mg/kg (intravenous bolus).~Maintenance of anesthesia: Continuous infusion of propofol and remifentanil. The infusion rate of propofol was adjusted according to BIS value. The infusion rate of remifentanil was 0.1-0.5µg/(kg.min) and adjusted according to the change of heart rate and blood pressure. Cisatracurium besylate was given as needed. Sufentanil 0.1μg/kg and flurbiprofen 50mg were given intravenously before the skin incision and suture respectively.
Study: NCT04985539

Intervention type: DEVICE
Intervention: Verily Study Watch
Description: Participants wear the Verily Study Watch for 2 years, for longitudinal data collection.
Study: NCT04243928

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesio taping
Description: apply kinesio taping on dorsi flexors muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio taping
Description: apply kinesio taping on dorsi flexors muscles
Study: NCT02539511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CI-581a

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CI-581b

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Enhancement Therapy (MET)
Study: NCT03890328

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: apply RF therapy to the treatment of splenic trauma
Study: NCT03705910

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Perceptive Rehabilitation
Description: In each session, over one hundred cones will be placed on a rigid wooden base using elastic strips. The patient will be asked to lie down supine on the material. Patients weigh will create pressure and reaction force to his/her body. Treatments will be 2 times a week till 8 weeks.~The therapist will ask the patient firstly to breathe normally and feel the pressure. The patient will then perform breathing exercises and active exercises (including stretching, warming up, and cooling down) under supervision. During the session, the therapist will ask about the pressure of the cones and will correct the patient's posture. At the end of each session, the therapist will photograph the patient's back with the aim of documenting the pressure and hyperaemic areas.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilisation Techniques
Description: A certified physiotherapist will perform mobilisation techniques. All participants in this group will receive treatment protocol according to the list on below. Treatments will be 2 times a week till 8 weeks.~For this treatment, the participant should lie on a bed and change their position according to the technique (supine, position or side-lying). Also, the therapist will be changing her position according to the technique. All technique will be on the range of motion limit. For releasing techniques the therapist will apply three-dimensional pressures till 3-5 minutes, with the feeling of relaxing therapist will change the limit for the next point.
Study: NCT01487993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Oral administration, 500 mg daily at week 1. Every week metformin dosage increases with 500 mg, to a maximum dose of 1000 mg bid. This maximum dose will be administered till the end of the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention
Description: Lifestyle intervention: 18 months physical therapy and dietary advice
Study: NCT00408005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IT, IV, or SC
Study: NCT01487993

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle intervention
Description: Lifestyle intervention: 18 months physical therapy and dietary advice
Study: NCT04619277

Intervention type: DEVICE
Intervention: drug-coated balloon
Description: drug-coated balloon
Study: NCT00408005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IT, IV, or SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IT, IV, or SC